Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Biblioteca Digital de Teses e Dissertações da UFC |
Texto Completo: | http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=19526 |
Resumo: | BACKGROUND:Acromegaly is a disorderassociated with increased mortality, mainly due to cardiovascular disease, caused by chronic excessive GH secretion. Regular echocardiographic assessment is recommended to evaluate cardiac morphological disorders, including valvopathy. One of the therapeutic options is the use of cabergoline (CAB). This medication has been associated with lesions to the cardiac valve apparatus when used in patients with ParkinsonÂs disease or Prolactinoma, but data on acromegalic patients are scant.OBJECTIVE:Compare the prevalence of valvopathy among patients with acromegaly who have used cabergoline and those who have not.METHODS:The present study is cross-sectional and observational analytical.Echocardiography was performed for two cardiologists blinded to treatment, and laboratory tests weremade and patientsâ medical records were reviewed for clinical data collection. Patients were divided into two groups according to usage (CAB group) or not (control group)of cabergoline. SPSS v17 was used for statistical analysis. RESULTS:Fifty two patientswere evaluated, 35 in the CAB group and 17 in the control group. The distribution of sex and age, and the prevalence of hypertension, diabetes and obesity were similar in both groups. In the CAB group, the period of drug administration was 36 Â 27 months, and cumulative dose was 262 Â 178mg. The prevalence of regurgitation in any valve was, for CAB group and Control group respectively 42,9 vs 23,5% (P=0,175, both observers). The prevalence of remodeling in any valve was37,1 vs 23,5% (P=0,326, observer 1) and 42,9 vs 23,5% (P=0,175, observer 2). CONCLUSION:In our study, the use of cabergoline was not associatedwith valvulopathy in patients with acromegaly. Our data do not support modification of current guidelines of echocardiographic evaluation in these patients according to the use of cabergoline. |
id |
UFC_b5ec9afa4dda60e397832ea6b065f239 |
---|---|
oai_identifier_str |
oai:www.teses.ufc.br:11388 |
network_acronym_str |
UFC |
network_name_str |
Biblioteca Digital de Teses e Dissertações da UFC |
spelling |
info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisEvaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegalyAvaliaÃÃo da associaÃÃo entre uso da cabergolina e a presenÃa de valvopatia em pacientes portadores de acromegalia2016-07-20Manoel Ricardo Alves Martins48034622320http://lattes.cnpq.br/3503117351197846Miguel Nasser Hissa03189821372http://lattes.cnpq.br/2536968092479804Carlos Roberto Martins Rodrigues Sobrinho32138350304http://lattes.cnpq.br/3976565864234541Eveline Gadelha Pereira Fontenele4431693335http://lattes.cnpq.br/275119963160817265893522320http://lattes.cnpq.br/1780387756616201Ludmilla Aline Guimaraes Moreira FariasUniversidade Federal do CearÃPrograma de PÃs-GraduaÃÃo em PatologiaUFCBRANATOMIA PATOLOGICA E PATOLOGIA CLINICABACKGROUND:Acromegaly is a disorderassociated with increased mortality, mainly due to cardiovascular disease, caused by chronic excessive GH secretion. Regular echocardiographic assessment is recommended to evaluate cardiac morphological disorders, including valvopathy. One of the therapeutic options is the use of cabergoline (CAB). This medication has been associated with lesions to the cardiac valve apparatus when used in patients with ParkinsonÂs disease or Prolactinoma, but data on acromegalic patients are scant.OBJECTIVE:Compare the prevalence of valvopathy among patients with acromegaly who have used cabergoline and those who have not.METHODS:The present study is cross-sectional and observational analytical.Echocardiography was performed for two cardiologists blinded to treatment, and laboratory tests weremade and patientsâ medical records were reviewed for clinical data collection. Patients were divided into two groups according to usage (CAB group) or not (control group)of cabergoline. SPSS v17 was used for statistical analysis. RESULTS:Fifty two patientswere evaluated, 35 in the CAB group and 17 in the control group. The distribution of sex and age, and the prevalence of hypertension, diabetes and obesity were similar in both groups. In the CAB group, the period of drug administration was 36  27 months, and cumulative dose was 262  178mg. The prevalence of regurgitation in any valve was, for CAB group and Control group respectively 42,9 vs 23,5% (P=0,175, both observers). The prevalence of remodeling in any valve was37,1 vs 23,5% (P=0,326, observer 1) and 42,9 vs 23,5% (P=0,175, observer 2). CONCLUSION:In our study, the use of cabergoline was not associatedwith valvulopathy in patients with acromegaly. Our data do not support modification of current guidelines of echocardiographic evaluation in these patients according to the use of cabergoline.INTRODUÃÃO:A acromegalia à uma doenÃa com elevada mortalidade, principalmente cardiovascular, causada pela secreÃÃocrÃnica excessiva de GH. AvaliaÃÃo periÃdica com ecocardiograma à recomendada de rotina devido ao aumento de alteraÃÃes morfolÃgicasnesses pacientes, incluindo valvopatia. Uma das opÃÃes terapÃuticas para essa patologia à a cabergolina (CAB). Esta medicaÃÃo vem sendo associadaà lesÃo valvar quando utilizada em pacientes com DoenÃa de Parkinson ou Prolactinoma, porÃm hà poucos dados em pacientes portadores de Acromegalia.OBJETIVOS:Comparar a prevalÃncia de alteraÃÃes valvares em portadores de acromegalia que usaram ou nÃo a cabergolina.MÃTODOS:Este estudo foi do tipo transversal, analÃtico observacional. Foi realizadoecocardiograma por dois observadores que desconheciam tratamento da doenÃa, exames laboratoriais e revisÃo de prontuÃrios. Os pacientes foram divididos em dois grupos, de acordo com o uso (grupo CAB) ou nÃo da cabergolina (grupo controle). Para anÃlise dos dados foi utilizado o programa SPSS v23. RESULTADOS:Foram avaliados52 pacientes, sendo 35 do grupo CAB e 17 do grupo controle. A distribuiÃÃo de sexo e idade, e a prevalÃncia de HAS, DM e Obesidade foram semelhantes nos dois grupos. No grupo CAB,o tempo de uso da droga foi 36  27 meses e a dose cumulativa de 262  178mg.Foi observado uma prevalÃncia de refluxo em qualquer valva no grupo CAB e controle respectivamente 42,9 vs 23,5% (P=0,175) por ambos os observadores.A prevalÃncia de alteraÃÃes morfolÃgicas nos grupos CAB e controle foi de 37,1 vs 23,5% (P=0,326, observador 1) e 42,9 vs 23,5% (P=0,175, observador 2). CONCLUSÃO:No nosso estudo o uso de cabergolina nÃo se associou a valvopatia em pacientes portadores de acromegalia. Nossos dados nÃo apoiam a modificaÃÃo do protocolo de acompanhamento ecocardiogrÃfico nos pacientes portadores de acromegalia de acordo com o uso ou nÃo de cabergolina.http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=19526application/pdfinfo:eu-repo/semantics/openAccessporreponame:Biblioteca Digital de Teses e Dissertações da UFCinstname:Universidade Federal do Cearáinstacron:UFC2019-01-21T11:32:03Zmail@mail.com - |
dc.title.en.fl_str_mv |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly |
dc.title.alternative.pt.fl_str_mv |
AvaliaÃÃo da associaÃÃo entre uso da cabergolina e a presenÃa de valvopatia em pacientes portadores de acromegalia |
title |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly |
spellingShingle |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly Ludmilla Aline Guimaraes Moreira Farias ANATOMIA PATOLOGICA E PATOLOGIA CLINICA |
title_short |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly |
title_full |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly |
title_fullStr |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly |
title_full_unstemmed |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly |
title_sort |
Evaluation of the association between the use of cabergoline and the presence of valvopathy in patients with acromegaly |
author |
Ludmilla Aline Guimaraes Moreira Farias |
author_facet |
Ludmilla Aline Guimaraes Moreira Farias |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
Manoel Ricardo Alves Martins |
dc.contributor.advisor1ID.fl_str_mv |
48034622320 |
dc.contributor.advisor1Lattes.fl_str_mv |
http://lattes.cnpq.br/3503117351197846 |
dc.contributor.referee1.fl_str_mv |
Miguel Nasser Hissa |
dc.contributor.referee1ID.fl_str_mv |
03189821372 |
dc.contributor.referee1Lattes.fl_str_mv |
http://lattes.cnpq.br/2536968092479804 |
dc.contributor.referee2.fl_str_mv |
Carlos Roberto Martins Rodrigues Sobrinho |
dc.contributor.referee2ID.fl_str_mv |
32138350304 |
dc.contributor.referee2Lattes.fl_str_mv |
http://lattes.cnpq.br/3976565864234541 |
dc.contributor.referee3.fl_str_mv |
Eveline Gadelha Pereira Fontenele |
dc.contributor.referee3ID.fl_str_mv |
4431693335 |
dc.contributor.referee3Lattes.fl_str_mv |
http://lattes.cnpq.br/2751199631608172 |
dc.contributor.authorID.fl_str_mv |
65893522320 |
dc.contributor.authorLattes.fl_str_mv |
http://lattes.cnpq.br/1780387756616201 |
dc.contributor.author.fl_str_mv |
Ludmilla Aline Guimaraes Moreira Farias |
contributor_str_mv |
Manoel Ricardo Alves Martins Miguel Nasser Hissa Carlos Roberto Martins Rodrigues Sobrinho Eveline Gadelha Pereira Fontenele |
dc.subject.cnpq.fl_str_mv |
ANATOMIA PATOLOGICA E PATOLOGIA CLINICA |
topic |
ANATOMIA PATOLOGICA E PATOLOGIA CLINICA |
dc.description.abstract.por.fl_txt_mv |
BACKGROUND:Acromegaly is a disorderassociated with increased mortality, mainly due to cardiovascular disease, caused by chronic excessive GH secretion. Regular echocardiographic assessment is recommended to evaluate cardiac morphological disorders, including valvopathy. One of the therapeutic options is the use of cabergoline (CAB). This medication has been associated with lesions to the cardiac valve apparatus when used in patients with ParkinsonÂs disease or Prolactinoma, but data on acromegalic patients are scant.OBJECTIVE:Compare the prevalence of valvopathy among patients with acromegaly who have used cabergoline and those who have not.METHODS:The present study is cross-sectional and observational analytical.Echocardiography was performed for two cardiologists blinded to treatment, and laboratory tests weremade and patientsâ medical records were reviewed for clinical data collection. Patients were divided into two groups according to usage (CAB group) or not (control group)of cabergoline. SPSS v17 was used for statistical analysis. RESULTS:Fifty two patientswere evaluated, 35 in the CAB group and 17 in the control group. The distribution of sex and age, and the prevalence of hypertension, diabetes and obesity were similar in both groups. In the CAB group, the period of drug administration was 36  27 months, and cumulative dose was 262  178mg. The prevalence of regurgitation in any valve was, for CAB group and Control group respectively 42,9 vs 23,5% (P=0,175, both observers). The prevalence of remodeling in any valve was37,1 vs 23,5% (P=0,326, observer 1) and 42,9 vs 23,5% (P=0,175, observer 2). CONCLUSION:In our study, the use of cabergoline was not associatedwith valvulopathy in patients with acromegaly. Our data do not support modification of current guidelines of echocardiographic evaluation in these patients according to the use of cabergoline. INTRODUÃÃO:A acromegalia à uma doenÃa com elevada mortalidade, principalmente cardiovascular, causada pela secreÃÃocrÃnica excessiva de GH. AvaliaÃÃo periÃdica com ecocardiograma à recomendada de rotina devido ao aumento de alteraÃÃes morfolÃgicasnesses pacientes, incluindo valvopatia. Uma das opÃÃes terapÃuticas para essa patologia à a cabergolina (CAB). Esta medicaÃÃo vem sendo associadaà lesÃo valvar quando utilizada em pacientes com DoenÃa de Parkinson ou Prolactinoma, porÃm hà poucos dados em pacientes portadores de Acromegalia.OBJETIVOS:Comparar a prevalÃncia de alteraÃÃes valvares em portadores de acromegalia que usaram ou nÃo a cabergolina.MÃTODOS:Este estudo foi do tipo transversal, analÃtico observacional. Foi realizadoecocardiograma por dois observadores que desconheciam tratamento da doenÃa, exames laboratoriais e revisÃo de prontuÃrios. Os pacientes foram divididos em dois grupos, de acordo com o uso (grupo CAB) ou nÃo da cabergolina (grupo controle). Para anÃlise dos dados foi utilizado o programa SPSS v23. RESULTADOS:Foram avaliados52 pacientes, sendo 35 do grupo CAB e 17 do grupo controle. A distribuiÃÃo de sexo e idade, e a prevalÃncia de HAS, DM e Obesidade foram semelhantes nos dois grupos. No grupo CAB,o tempo de uso da droga foi 36  27 meses e a dose cumulativa de 262  178mg.Foi observado uma prevalÃncia de refluxo em qualquer valva no grupo CAB e controle respectivamente 42,9 vs 23,5% (P=0,175) por ambos os observadores.A prevalÃncia de alteraÃÃes morfolÃgicas nos grupos CAB e controle foi de 37,1 vs 23,5% (P=0,326, observador 1) e 42,9 vs 23,5% (P=0,175, observador 2). CONCLUSÃO:No nosso estudo o uso de cabergolina nÃo se associou a valvopatia em pacientes portadores de acromegalia. Nossos dados nÃo apoiam a modificaÃÃo do protocolo de acompanhamento ecocardiogrÃfico nos pacientes portadores de acromegalia de acordo com o uso ou nÃo de cabergolina. |
description |
BACKGROUND:Acromegaly is a disorderassociated with increased mortality, mainly due to cardiovascular disease, caused by chronic excessive GH secretion. Regular echocardiographic assessment is recommended to evaluate cardiac morphological disorders, including valvopathy. One of the therapeutic options is the use of cabergoline (CAB). This medication has been associated with lesions to the cardiac valve apparatus when used in patients with ParkinsonÂs disease or Prolactinoma, but data on acromegalic patients are scant.OBJECTIVE:Compare the prevalence of valvopathy among patients with acromegaly who have used cabergoline and those who have not.METHODS:The present study is cross-sectional and observational analytical.Echocardiography was performed for two cardiologists blinded to treatment, and laboratory tests weremade and patientsâ medical records were reviewed for clinical data collection. Patients were divided into two groups according to usage (CAB group) or not (control group)of cabergoline. SPSS v17 was used for statistical analysis. RESULTS:Fifty two patientswere evaluated, 35 in the CAB group and 17 in the control group. The distribution of sex and age, and the prevalence of hypertension, diabetes and obesity were similar in both groups. In the CAB group, the period of drug administration was 36 Â 27 months, and cumulative dose was 262 Â 178mg. The prevalence of regurgitation in any valve was, for CAB group and Control group respectively 42,9 vs 23,5% (P=0,175, both observers). The prevalence of remodeling in any valve was37,1 vs 23,5% (P=0,326, observer 1) and 42,9 vs 23,5% (P=0,175, observer 2). CONCLUSION:In our study, the use of cabergoline was not associatedwith valvulopathy in patients with acromegaly. Our data do not support modification of current guidelines of echocardiographic evaluation in these patients according to the use of cabergoline. |
publishDate |
2016 |
dc.date.issued.fl_str_mv |
2016-07-20 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
status_str |
publishedVersion |
format |
masterThesis |
dc.identifier.uri.fl_str_mv |
http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=19526 |
url |
http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=19526 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal do Cearà |
dc.publisher.program.fl_str_mv |
Programa de PÃs-GraduaÃÃo em Patologia |
dc.publisher.initials.fl_str_mv |
UFC |
dc.publisher.country.fl_str_mv |
BR |
publisher.none.fl_str_mv |
Universidade Federal do Cearà |
dc.source.none.fl_str_mv |
reponame:Biblioteca Digital de Teses e Dissertações da UFC instname:Universidade Federal do Ceará instacron:UFC |
reponame_str |
Biblioteca Digital de Teses e Dissertações da UFC |
collection |
Biblioteca Digital de Teses e Dissertações da UFC |
instname_str |
Universidade Federal do Ceará |
instacron_str |
UFC |
institution |
UFC |
repository.name.fl_str_mv |
-
|
repository.mail.fl_str_mv |
mail@mail.com |
_version_ |
1643295234322333696 |